Literature DB >> 20097293

D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.

Mette Skinbjerg1, Jeih-San Liow, Nicholas Seneca, Jinsoo Hong, Shuiyu Lu, Annika Thorsell, Markus Heilig, Victor W Pike, Christer Halldin, David R Sibley, Robert B Innis.   

Abstract

Dopamine released by amphetamine decreases the in vivo binding of PET radioligands to the dopamine D(2) receptor. Although concentrations of extracellular dopamine largely return to baseline within 1 to 2 h after amphetamine treatment, radioligand binding remains decreased for several hours. The purpose of this study was to determine whether the prolonged decrease of radioligand binding after amphetamine administration is caused by receptor internalization. To distinguish dopamine displacement from receptor internalization, we used wild-type and arrestin3 (arr3) knockout mice, which are incapable of internalizing D(2) receptors. In addition, we used both the D(2) selective agonist [(11)C]MNPA (which is thought to bind to the high affinity state of the receptor) and the D(2) selective antagonist [(18)F]fallypride (which does not differentiate between high and low affinity state). After an initial baseline scan, animals were divided in three groups for a second scan: either 30 min or 4 h after amphetamine administration (3 mg/kg, i.p.) or as retest. At 30 min, [(11)C]MNPA showed greater displacement than [(18)F]fallypride, but each radioligand gave similar displacement in knockout and wild-type mice. At 4 h, the binding of both radioligands returned to baseline in arr3 knockout mice, but remained decreased in wild-type mice. Radioligand binding was unaltered on retest scanning. Our results suggest that the prolonged decrease of radioligand binding after amphetamine is mainly due to internalization of the D(2) receptor rather than dopamine displacement. In addition, this study demonstrates the utility of small animal PET to study receptor trafficking in vivo in genetically modified mice. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097293      PMCID: PMC2838946          DOI: 10.1016/j.neuroimage.2010.01.055

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  27 in total

Review 1.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

2.  Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride.

Authors:  Nicholas Seneca; Sjoerd J Finnema; Lars Farde; Balázs Gulyás; Håkan V Wikström; Christer Halldin; Robert B Innis
Journal:  Synapse       Date:  2006-04       Impact factor: 2.562

3.  Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist.

Authors:  J L Neumeyer; Y G Gao; N S Kula; R J Baldessarini
Journal:  J Med Chem       Date:  1990-12       Impact factor: 7.446

4.  Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.

Authors:  Nathalie Ginovart; Laurent Galineau; Matthaeus Willeit; Romina Mizrahi; Peter M Bloomfield; Philip Seeman; Sylvain Houle; Shitij Kapur; Alan A Wilson
Journal:  J Neurochem       Date:  2006-04-05       Impact factor: 5.372

5.  Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.

Authors:  A Malmberg; E Jerning; N Mohell
Journal:  Eur J Pharmacol       Date:  1996-05-06       Impact factor: 4.432

6.  Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein.

Authors:  Paul Cumming; Dean F Wong; Nicholas Gillings; John Hilton; Ursula Scheffel; Albert Gjedde
Journal:  J Cereb Blood Flow Metab       Date:  2002-05       Impact factor: 6.200

7.  Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.

Authors:  Sjoerd J Finnema; Christer Halldin; Benny Bang-Andersen; Balázs Gulyás; Christoffer Bundgaard; Håkan V Wikström; Lars Farde
Journal:  Synapse       Date:  2009-05       Impact factor: 2.562

8.  Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.

Authors:  Patrick N McCormick; Shitij Kapur; Philip Seeman; Alan A Wilson
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

9.  Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.

Authors:  Y G Gao; R J Baldessarini; N S Kula; J L Neumeyer
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

10.  beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking.

Authors:  T A Kohout; F S Lin; S J Perry; D A Conner; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  38 in total

1.  Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI.

Authors:  Christin Y Sander; Jacob M Hooker; Ciprian Catana; Bruce R Rosen; Joseph B Mandeville
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

2.  Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain.

Authors:  Nora D Volkow; Dardo Tomasi; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Helene Benveniste; Ron Kim; Panayotis K Thanos; Sergi Ferré
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

Review 3.  Molecular imaging of microglia/macrophages in the brain.

Authors:  Sriram Venneti; Brian J Lopresti; Clayton A Wiley
Journal:  Glia       Date:  2012-05-21       Impact factor: 7.452

4.  Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction.

Authors:  Diana Martinez; Phillip A Saccone; Fei Liu; Mark Slifstein; Daria Orlowska; Alex Grassetti; Stephanie Cook; Allegra Broft; Ronald Van Heertum; Sandra D Comer
Journal:  Biol Psychiatry       Date:  2011-10-19       Impact factor: 13.382

Review 5.  Quantitative Rodent Brain Receptor Imaging.

Authors:  Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

6.  Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors.

Authors:  Jan-Peter van Wieringen; Martin C Michel; Henk M Janssen; Anton G Janssen; Philip H Elsinga; Jan Booij
Journal:  EJNMMI Res       Date:  2014-10-07       Impact factor: 3.138

Review 7.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

Review 8.  Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?

Authors:  Mette Skinbjerg; David R Sibley; Jonathan A Javitch; Anissa Abi-Dargham
Journal:  Biochem Pharmacol       Date:  2011-09-16       Impact factor: 5.858

Review 9.  News and views on in-vivo imaging of neurotransmission using PET and MRI.

Authors:  Christin Y Sander; Swen Hesse
Journal:  Q J Nucl Med Mol Imaging       Date:  2017-07-27       Impact factor: 2.346

Review 10.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.